Member Info for Yorkshirepragma

Https://www.fiercepharma.com/pharma/patient-cliffs-divestitures-and-biotechs-maturing-its-prime-time-ma-analysts

Note ‘ urgency in quest for deals….”

That’s All folks.

GLA

Https://www.biopharmadive.com/news/sandoz-novartis-spin-off-separation-generic-drug/695610/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202023-10-04%20BioPharma%20Dive:%20Commercialization%20%5Bissue:55138%5D&utm_term=BioPharma%20Dive:%20Commercialization

Significant …

Always read this stuff with interest, however the most factual and relevant point is seen in 13=m into the VOX / AS interview when it’s stated..’ there’s an uptick in interest (in deals etc).

Forget the rest,,that’s a signal for the future .

GLA

And so Takeda needs additional options…as all BP do.

GLA

How to you ‘value’ formally , …uptick in interest …more or less .every LP seeking oncology ( 20+) opportunities….wait on..

GLA

By far the most ‘interesting’ commentary of the week…ignore at one’s peril…

GLA

13m ….uptick in ( Pharma ) interest in deals…AS

Apologies typos…celebratory old peculiar to blame…

‘AS YOU CAN IMAGINE WE ARE SEEING AN UPTICK IN COMMERCIAL INTEREST…’quote 12 min in Alastair S in response to what are the options/ Parma interests etc from Mr Hill..

Quote of the day…

…a ariba

Dr Alastair Smith, Chief Executive of Avacta Group plc commented:

"I believe that we are on the verge of a paradigm shift in how chemotherapy is delivered to cancer patients.

Https://www.reatapharma.com/home/default.aspx

Acquired for $7.3 bn..

Next week or so…wait on.

Tim, keep of the old peculiar…but there have been several early stage pre2 buyouts for high prospects @ $2bn+/-.

My guess Alastair et al will see this through, strike some sig.deals ,and anybody’s guess if OR is solid.

Upping Stateside interest ,and institutional investor base key.

GLA

As an ‘old bold’ pharma bod, look this is a tremendous platform. That’s much more than an AVA 6000 , even tho that’s likely brilliant.

Tremendous Pharma interns here’s, commercially and scientifically.

GLA

Just take a minute to put yourself in the shoes of the brave folk partaking in the trails.

Have some common.

As well as consider the potential interest of BP. It’s a platform, with prospects…a rarity.

GLA

W ,interesting (early morning ? ) balanced thesis.

Just add in the interest in LP in a ‘rare’ strategic platform, and you’re there. Which could change the game in a trice.

Expansion , good news.

USA always progressive ime.especially with a high prospect of success.

Bella. Well said, unles you’ve experienced severe illness it’s only reflection.

Heartening to re read the data .

It looks a great step forward .

Regards

The data continue to show a very favourable safety profile for the tumour targeted chemotherapy and several patients in cohort 5 and earlier cohorts remain on treatment as their disease has not progressed.

A total of 29 patients with a range of advanced and/or metastatic solid tumours have now been dosed at the clinical trial in sites in the UK and United States. On the basis of the very favourable safety profile of AVA6000 in the study to date, the Safety Data Monitoring Committee (SDMC) has recommended continuation to the sixth dose cohort at 310 mg/m2, which is equivalent to 2.7 times the standard dose of doxorubicin.